Intensity Therapeutics Restarts Phase 2 TNBC Trial
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
Breast Cancer
Advertisement
PreludeDx Expands DCIS Education Through New Collaboration
LAGUNA HILLS, Calif., July 7, 2026 PreludeDx™, a leader in precision diagnostics for early-stage breast cancer, has announced a...
Movmedix Enters U.S. Market with FDA-Cleared LARS® Technology
ARC-SUR-TILLE, France, July 6, 2026 Movmedix, the French orthopedic medical technology company behind the globally recognized LARS® synthetic ligament...
IceCure Expands ProSense Cryoablation in Brazil After FDA Clearance
CAESAREA, Israel, July 6, 2026 IceCure Medical Ltd. has announced accelerating commercial adoption of its ProSense™ cryoablation system in...
Natera Signatera Predicts Chemotherapy Benefit in CRC Patients
AUSTIN, Texas, July 6, 2026 Natera, Inc. has announced the publication of groundbreaking clinical data in JAMA Oncology demonstrating...
Advertisements
Astex and Genentech Partner to Advance Breast Cancer Drugs
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Gilead Sciences Wins FDA Approval for Trodelvy in First-Line mTNBC
FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Delphi Diagnostics Validates EAI for Paclitaxel Benefit
HOUSTON, Texas, June 22, 2026 Delphi Diagnostics has announced the publication of new clinical findings validating the predictive power...
Zetagen Therapeutics Reports Positive Phase 2a ZetaMet Results
AUSTIN, Texas, June 9, 2026 Zetagen Therapeutics announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™...
Advertisement
